Testicular quality performance indicators | Target (%) |
1. Radiological staging—proportion of patients who undergo CT scanning, ideally contrast-enhanced CT, of the chest, abdomen and pelvis within 3 weeks of orchidectomy. | 95 |
2. Preoperative assessment—proportion of patients who undergo preoperative assessment of the testicle which includes (1) serum tumour markers (STM) and (2) testicular ultrasound. | 95 |
3. Primary orchidectomy—proportion of patients who undergo primary orchidectomy within 2 weeks of ultrasonographic diagnosis. (Hospital of surgery) | 95 |
4. Multidisciplinary team meeting—proportion of patients discussed at an MDT meeting to agree a definitive management plan after orchidectomy. | 95 |
5. Pathology reporting—proportion of patients undergoing orchidectomy where the pathology report contains full information (as per the Royal College of Pathologists (RCoP) data set).19 | 90 |
6. Quality of adjuvant treatment—proportion of patients with stage I seminoma receiving adjuvant single-dose carboplatin within 8 weeks of orchidectomy. | 95 |
7. Serum tumour markers—proportion of patients with metastatic testicular cancer who undergo STMs 2 weeks before starting chemotherapy. | 98 |
8. Systemic therapy—proportion of patients with metastatic testicular cancer who undergo systemic anticancer therapy (SACT) within 3 weeks of an MDT decision to treat with SACT. | 95 |
9. CT scanning for surveillance patients—proportion of patients with ‘low-risk’ testicular non-seminomatous germ cell tumour (NSGCT) (or mixed) under surveillance who undergo at least three CT scans of the abdomen±chest and pelvis within 14 months of diagnosis. (Note: year 1 reporting) | 85 |
10a. 30-day mortality (orchidectomy)—proportion of patients who die within 30 days of treatment for testicular cancer. (Hospital of surgery) | <5 |
10b. 30-day mortality (chemotherapy)—proportion of patients who die within 30 days of treatment for testicular cancer. | <5 |
10c. 30-day mortality (radiotherapy)—proportion of patients who die within 30 days of treatment for testicular cancer. | <5 |
11. Clinical trial—all patients should be considered for participation in available clinical trials, wherever eligible. | >15 |
MDT, multidisciplinary team; QPI, quality performance indicator.